RT Journal Article
SR Electronic
T1 Immune Modulation in Solid Tumors: A Phase 1b Study of RO6870810 (BET Inhibitor) and Atezolizumab (PD-L1 Inhibitor)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.28.24309665
DO 10.1101/2024.07.28.24309665
A1 Marbach, Daniel
A1 Brouer-Visser, Jurriaan
A1 Brennan, Laura
A1 Wilson, Sabine
A1 Davydov, Iakov I
A1 Staedler, Nicolas
A1 Duarte, José
A1 Quetglas, Iris Martinez
A1 Nüesch, Eveline
A1 Cañamero, Marta
A1 Chesné, Evelyne
A1 Au-Yeung, George
A1 Hamilton, Erika
A1 Lheureux, Stephanie
A1 Richardson, Debra L
A1 Spanggaard, Iben
A1 Gomes, Bruno
A1 Franjkovic, Izolda
A1 DeMario, Mark
A1 Kornacker, Martin
A1 Lechner, Katharina
YR 2024
UL http://medrxiv.org/content/early/2024/07/29/2024.07.28.24309665.abstract
AB Purpose Bromodomain and extra-terminal domain (BET) inhibitors (BETi) have demonstrated epigenetic modulation capabilities, specifically in transcriptional repression of oncogenic pathways. Preclinical assays suggest that BETi potentially attenuates the PD1/PD-L1 immune checkpoint axis, supporting its combination with immunomodulatory agents.Patients and Methods A Phase 1b clinical trial was conducted to elucidate the pharmacokinetic and pharmacodynamic profiles of the BET inhibitor RO6870810, as monotherapy and in combination with the PD-L1 antagonist atezolizumab, in patients with advanced ovarian carcinomas and triple-negative breast cancer (TNBC). Endpoints included maximum tolerated dosages, adverse event profiling, pharmacokinetic evaluations, and antitumor activity. Pharmacodynamic and immunomodulatory effects were assessed in tumor tissue (by immunohistochemistry and RNA-seq) and in peripheral blood (by flow cytometry and cytokine analysis).Results The study was terminated prematurely due to a pronounced incidence of immune-related adverse effects in patients receiving combination of RO6870810 and atezolizumab. Anti-tumor activity was limited to 2 patients (5.6%) showing partial response. Although target engagement was confirmed by established BETi pharmacodynamic markers in both blood and tumor samples, BETi failed to markedly decrease tumor PD-L1 expression and had a suppressive effect on anti-tumor immunity. Immune effector activation in tumor tissue was solely observed with the atezolizumab combination, aligning with this checkpoint inhibitor’s recognized biological effects.Conclusions The combination of BET inhibitor RO6870810 with the checkpoint inhibitor atezolizumab presents an unfavorable risk-benefit profile for ovarian cancer and TNBC (triple-negative breast cancer) patients due to the increased risk of augmented or exaggerated immune reactions, without evidence for synergistic anti-tumor effects.Trial registration ClinicalTrials.gov ID NCT03292172Competing Interest StatementAuthors1-5 are employees and/or shareholders of F Hoffmann-La Roche. All authors have received grants and non-financial or other support from F. Hoffmann-La Roche, during the conduct of the study. Editorial support, funded by the sponsor, was provided by an independent medical writer under the guidance of the authors.Clinical TrialNCT03292172Funding StatementThis study was funded by F. Hoffmann-La Roche Ltd.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by each center's ethics committee or institutional review board, and the study was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines. All participants provided written informed consent. List of independent Ethics Committees/Institutional Review Boards with dates of approval: (1) University Health Network Research Ethics Board, 700 Bay Street, 17th Floor, Suite 1700, M5G 1Z6, Toronto, Ontario, CANADA (Approval: 12-Oct-2017); (2) Dana Farber Cancer Institute/Dana-Farber/Harvard Cancer center, 450 Brookline Ave, OS-200, Boston, MA, 02215, UNITED STATES (Approval: 07-Nov-2017); (3) Western Institutional Review Board, 1019 39th Avenue SE, Ste 120, Puyallup, WA, 98374, UNITED STATES (Approval: 18-Oct-2017); (4) Peter MacCallum Cancer Centre Ethics Committee, 305 Grattan Street, 3000, Melbourne, Victoria, AUSTRALIA (Approval: 01-Aug-2018); (5) IntegReview Ethical Review Board, 3001 S. Lamar Blvd., Suite 210, Austin, TX, 78704, UNITED STATES (Approval: 03-Sept-2018).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesQualified researchers may request access to individual participant-level data through the clinical study data request platform (https://vivli.org/ourmember/roche/). Further details on F. Hoffmann-La Roche Ltd's criteria for eligible studies are available at https://vivli.org/members/ourmembers/. For further details on F. Hoffmann-La Roche Ltd's Global Policy on the Sharing of Clinical Information and the procedure to request access to related clinical study documents, see https://www.roche.com/innovation/process/clinical-trials/data-sharing